MedTrace Logo

Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease

NCT00285077 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 390

Last updated 2008-12-23

No results posted yet for this study

Summary

The primary objective is to assess the long term safety/tolerability of 4 mg/day of SR57667B in comparison to placebo in patients with mild-to-moderate Alzheimer's Disease (AD).

A secondary objective is to describe the long term progression of Alzheimer's symptoms in patients treated by 4 mg/day of SR57667B.

Conditions

  • Alzheimer Disease

Interventions

DRUG

SR57667B

Sponsors & Collaborators

Principal Investigators

  • Serge GAUTHIER, MD · Scientific Advisory Committee

  • Jean-Marc ORGOGOZO, MD · Scientific Advisory Committee

  • Philip SCHELTENS, MD · Scientific Advisory Committee

  • Bengt WINBLAD, MD · Scientific Advisory Committee

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2006-11-30
Completion
2006-11-30

Countries

  • Canada
  • Denmark
  • Finland
  • France
  • Germany
  • South Africa
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00285077 on ClinicalTrials.gov